Improving Consistency and Scalability in AAV Manufacturing

The most consequential operational challenges in viral vector manufacturing are manual processing limitations, lack of standardization, batch-to-batch variability, high cost of goods, and supply chain constraints.

These challenges are driven primarily by reliance on transient transfection methods that employ plasmid-based systems, creating bottlenecks in sourcing, scalability, and production economics.

By offering a more predictable and scalable alternative to multi-plasmid transient transfection, the Xcite AAV stable PCL platform is designed to improve titer, robustness, and scalability, which can lead to reduced process variability, reduced operational complexity, smoother tech transfer, enhanced product quality, and lower cost of goods.

The platform’s proprietary vector design enables tight, leak-proof expression control through inducible helper and replication genes, thereby minimizing the cytotoxicity associated with these proteins before AAV production is induced. This process also supports the simultaneous multiplexing of multiple vectors to improve the efficiency of the cell line construction process.

In beta testing, the technology has demonstrated a 10- to 15-fold increase in titer compared with traditional transfection-based AAV manufacturing methods. These productivity improvements directly translate into lower cost per dose, improved facility throughput and process consistency, and greater confidence during scale-up and tech transfer.

The PCL approach entails the stable integration of all three sets of genes required for AAV production into a proprietary suspension HEK-293 clonal cell line. AAV production is triggered through chemical induction, eliminating the need for expensive Good Manufacturing Practice (GMP) plasmids and transfection reagents that drive high costs in transient transfection methods.

Importantly, the PCL platform can also deliver significant increases in AAV titer, depending on the serotype and therapeutic gene, which can translate into substantial cost reductions. When combined with the economic gains associated with increased manufacturing scale, the process can be a major contributor to overall cost reduction.

Traditional transfection processes create several challenges in maintaining product quality and consistency.

First, the heterogeneous transfection complex inherently introduces varying copy numbers and ratios of plasmid DNA into individual producer cells, leading to poor genome packaging efficiency and reduced AAV product quality.

Second, the transfection process involves large amounts of plasmid DNA tightly complexed with transfection reagents, adding a significant burden to downstream purification processes to remove impurities.

Third, process efficiency is often variable due to perturbations in producer cell homeostasis, transfection complex quality and stability, and process control. This issue is exacerbated as production scale increases, resulting in variable productivity from batch to batch.

In contrast, the PCL approach overcomes these challenges by replacing the transfection process with a simple, robust small-molecule-mediated induction process using a monoclonal cell line. The vector design of the inducible AAV production genes is optimized for robust yet finely tuned expression through fixed DNA copy numbers and ratios in each cell. This enables consistent, scalable AAV production with high titer, quality, and purity.

From our discussions with drug developers and our broad perspective across the industry, we see the primary hurdles as limited product manufacturability and high cost of goods. This often stems from issues related to vector immunogenicity and toxicity, payload efficiency, and constraints with Chemistry, Manufacturing, and Control (CMC).

To overcome these issues, developers turn to contract development and manufacturing organizations (CDMOs) like Lonza, which can design efficient, scalable processes for gene therapy manufacturing.

Specifically, CDMOs can develop platform-based approaches such as the Xcite AAV stable PCL technology, which enable standardized, transferable processes and allow programs to move efficiently from clinical to commercial production across global sites.

With this approach, gene therapy developers can flexibly scale production and proactively respond to market trends favoring more potent treatments for larger patient populations.

Advances include innovative bioengineering solutions such as the Xcite AAV stable PCL technology and digitalized platforms for process development. In formulation and development, technologies like Xcite AAV PCL improve consistency, scalability, and operational efficiency while helping reduce cost and variability and accelerate development timelines.

Beyond the cleanroom, we’re seeing greater use of data, automation, and advanced analytics, enabling more reliable manufacturing and smoother tech transfer across sites.

These advances are particularly critical for oncology and neurodegenerative diseases, where treating larger patient populations and enabling higher or systemic dosing require the ability to manufacture high volumes of AAV with consistent potency and quality.

This scalability is key to making such therapies clinically and commercially viable in these complex indications.

In discussions about commercialization with our industry peers, there has been a perceptible shift from early-stage proof of concept to scaled and sustainable delivery.

While manufacturing bottlenecks and high capital costs continue to dominate these discussions, we have also seen a heightened focus on standardization of platform processes, automated manufacturing, supply chain logistics, and enhancing market access and reimbursement. These issues are expected to remain in the spotlight as the cell and gene therapy modality continues to mature.

The introduction to this interview includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.